Evidence map›Paper›PMID 41209933›Full record

ArticleCureus2025

A Case of Immunotherapy-Induced Balanitis.

Terrence Sun, Danielle Brazel, Aditya Sarvaria

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Terrence SunHematology and Medical Oncology, Scripps Clinic, San Diego, USA.
Danielle BrazelHematology and Medical Oncology, Scripps Clinic, San Diego, USA.
Aditya SarvariaHematology and Medical Oncology, Scripps Clinic, San Diego, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy is indicated in a variety of different cancers with wide-ranging adverse events. Although dermatitis can be common, serious dermatologic complications (such as Stevens-Johnson syndrome) have also been reported. In this case report we present a case of balanitis caused by pembrolizumab, briefly review the current literature on more common dermatologic immunotherapy toxicities, and discuss the more common causes and treatments of balanitis. Although drug eruptions commonly respond to discontinuation of the offending agent, here we were able to treat with topical agents, such as steroid cream and mupirocin ointment. The ability to treat the balanitis without needing to discontinue the patient's immunotherapy highlights the success in both controlling the cancer and the treatment-related toxicity.

Indexed as

balanitiscancer immunotherapyimmunotherapy-related adverse eventslung cancerpembrolizumab cutaneous side effect

Identifiers

PMID41209933
PMCPMC12595996

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.